Differential expression of circulating miRNAs in maternal plasma in pregnancies with fetal macrosomia

QINYU GE1, YANAN ZHU1, HAILING LI3, FEI TIAN1, XUEYING XIE1 and YUNFEI BAI2

1Key Laboratory for Child Development and Learning Science, Ministry of Education, Research Center for Learning Science, Southeast University; 2State Key Laboratory of Bioelectronics, Southeast University, Nanjing 2100096; 3Department of Gynecology and Obstetrics, Zhongda Hospital, Southeast University, Nanjing 210009, P.R. China

Received August 13, 2014; Accepted October 21, 2014

DOI: 10.3892/ijmm.2014.1989

Abstract. Macrosomia is associated with problems at birth and has life-long health implications for the infant. The aim of this study was to profile the plasma microRNAs (miRNAs or miRs) and evaluate the potential of circulating miRNAs to predict fetal macrosomia. The expression levels of miRNAs in plasma samples obtained from pregnant women with fetal macrosomia and from women with normal pregnancies (controls) were analyzed using TaqMan Low-Density Arrays (TLDA) followed by quantitative reverse transcription polymerase chain reaction (RT-qPCR) validation and analysis. The TLDA data revealed that 143 miRNAs were differentially expressed in the plasma samples from pregnant women with fetal macrosomia compared with the controls (43 upregulated and 100 downregulated miRNAs). Twelve of these miRNAs were selected for RT-qPCR analysis. Receiver operational characteristic (ROC) curve analysis indicated that several miRNAs (e.g., miR-141-3p and miR-200c-3p) were clearly distinguished between pregnancies with fetal macrosomia and other types of abnormal pregnancy and healthy pregnancies with high sensitivity and specificity (AUC >0.9). The expression of miRNA clusters also showed a similar trend in pregnancies with fetal macrosomia. This study provides a platform for profiling circulating miRNAs in maternal plasma. Our data also suggest that altered levels of maternal plasma miRNAs have great potential to serve as non-invasive biomarkers and as a mechanistic indicator of abnormal pregnancies.

Introduction

Pregnancies with a macrosomic fetus comprise a subgroup of high-risk pregnancies, which have been variously defined as pregnancies in which the birth weight of the newborn is greater than 4,000, 4,500 or 5,000 g, while this fails to take gestational age and gender into consideration (1,2). Another definition of macrosomia as a birth weight >90th percentile for gestation or >97.75th percentile of a reference population corrected for gestational age and gender has been proposed. However, in light of the substantially increased adverse birth outcomes associated with a birth weight > 4,500 g, as well as its ease of use, this definition has been widely adopted (3,4). Maternal obesity, impaired glucose tolerance and gestational diabetes contribute to infant macrosomia; furthermore, the risk is higher in aboriginal populations (5-7). Macrosomia affects 50% of pregnancies complicated by maternal diabetes (8,9). It is also associated with problems at birth and has life-long health implications for the infant, including an increased risk of developing cardiovascular disease and diabetes in adulthood (10-12). Although the incidence of macrosomia is high amongst women with diabetes, there is currently no reliable method to predict who will deliver macrosomic infants. Understanding the factors that affect this placental growth is essential for the development of novel therapies. The study of circulating nucleic acid in maternal plasma may provide solutions for determining the development of macrosomia; for example, fetal macrosomia in pregnancies complicated by diabetes has been shown to accompany an increase in the levels of fetal deoxyribonucleic acid (DNA) and proteins in animal model systems (13).

MicroRNAs (miRNAs or miRs) are newly identified molecules that are common 18-25 nucleotide-long, non-coding RNA molecules that post-transcriptionally regulate gene expression by base-pairing with the 3′ untranslated region of complementary messenger RNA targets. miRNAs have been identified in animal cells and have been reported to play a role in numerous vital processes, including embryonic development, cellular differentiation and proliferation and apoptosis (14,15). They are produced in cells and tissues and have also been detected in the circulation recently. The aberrant expression of miRNAs has been associated with disease development and the recent discovery of miRNAs in serum and plasma has stimulated interest in their potential for use as circulating biomarkers (16). There is an increasing number of publications describing circulating miRNA biomarkers of breast, colon, gastric, lung, oral, ovarian, pancreatic, prostate, tongue and squamous cell cancers (17), stroke and neurological disorders (18), diabetes,
heart failure and lupus erythematosus (19,20). Plasma/serum miRNA biomarkers have the advantage of stabilization and relative abundance, and their small size and consistent structure enables the application of quantitative multiplex assays using quantitative polymerase chain reaction (qPCR).

Circulating miRNA profiles or ‘signatures’ are altered in several disease states; thus, they are effective tools for the diagnosis and prognosis of diseases, including cardiovascular disease (21) and different forms of cancer (22-24). Establishing the plasma miRNA signature of pregnant women may therefore provide a non-invasive method for predicting fetal macrosomia.

In this study, we used TaqMan Low-Density Arrays (TLDAs) and reverse transcription qPCR (RT-qPCR) to profile the plasma miRNAs differentially expressed in pregnant women with fetal macrosomia and women with normal pregnancies as the controls, and explored the potency of plasma miRNA expression profiles as an early diagnostic biomarker for fetal macrosomia.

Materials and methods

Sample collection and processing. Peripheral blood samples from 45 pregnant women collected during their second trimester (18-28 weeks of gestational age) were selected; the neonates of these women were later diagnosed with macrosomia at delivery. Another 30 samples from women with normal healthy pregnancies were collected during the same trimester as the controls. Furthermore, an additional 16 samples from pregnant women with preeclampsia at their second gestational ages (22-28 weeks) were also collected for differential diagnosis by qPCR (some of them were later diagnosed with preeclampsia). All the samples were recruited from Zhongda Hospital, Southeast University (Nanjing, China) and Wuxi Maternity and Child Health Care Hospital (Wuxi, China) between November 2011 and July 2013. Among the collected samples, 10 samples from pregnant women with fetal macrosomia and 10 samples from women with normal pregnancies (control) were selected and pooled as samples for use in TLDAs. Samples from 35 pregnant women with fetal macrosomia and from 20 women with normal pregnancies were used in RT-qPCR for validation of the array data. Although there is no consensus on the definition of fetal macrosomia, in light of the substantially increased adverse birth outcomes associated with a birth weight >4,500 g, as well as its ease of use, this definition has been widely adopted (4). In the present study, the diagnosis of macrosomia was in accordance with this standard. This study was approved by the Ethics Committee of Zhongda Hospital, Southeast University and written informed consent was obtained from all the pregnant women prior to participation.

EDTA blood was centrifuged at 1,600 x g for 10 min at 4°C, and plasma was transferred to new tubes followed by further centrifugation at 16,000 x g for 10 min at 4°C. The separated plasma samples were subjected to RNA isolation or placed in a -80°C freezer for short-term storage. Two plasma pools of the macrosomia and control groups were created by combining 10 samples (50 µl of sample) and mixing by inversion and 500 µl of each of these pools were used to extract RNA for TLDAs.

RNA extraction. Total RNA containing small RNA was extracted from 500 ml of plasma using TRizol® LS Reagent (Invitrogen, Carlsbad, CA, USA) and the miRNeasy Mini kit (Qiagen, Hilden, Germany) with some modifications according to Ng's report (25). Briefly, TRizol LS Reagent was added to the plasma samples in volumetric ratios as previously described (26). Following phase separation by the addition of chloroform and centrifugation, 1.5 vol of 100% ethanol was added to the aqueous phase, and the mixture was loaded onto the miRNeasy column (Qiagen) according to the manufacturer's instructions. The final elution volume was 30 µl. The concentrations of all RNA samples were quantified using the Qubit® RNA HS Assay kit with the Qubit 2.0 fluorometer (Life Technologies, Grand Island, NY, USA) according to the manufacturer's instructions. The concentration of the RNA extracted from the plasma ranged from 3.68 to 53.84 ng/ml.

miRNA profiling using TLDAs. The ABI TaqMan miRNA Low-Density Arrays (Applied Biosystems, Foster City, CA, USA) were selected as the platform for global miRNA expression profiling. Approximately 500 ng of total RNA was reverse transcribed into complementary DNA (cDNA) using the TaqMan microRNA reverse transcription kit and the miRNA Megaplex™ RT pool set A and B, a set of 2 pre-defined pools of up to 380 stem-loop RT primers per pool that enable the simultaneous synthesis of cDNA for mature miRNAs. The cDNA products were loaded onto TaqMan Human microRNA A + B Cards Set version 3.0, enabling the simultaneous quantification of 754 human miRNAs. TLDAs were performed on the ABI 7900HT Instrument (Applied Biosystems). Normalization was performed with the small nuclear RNAs (snRNAs) U44, U48 and U6. Quantitative miRNA expression data were acquired and normalized using ABI 7900HT SDS software (Applied Biosystems).

RT-qPCR. RT-qPCR was used to detect and quantify individual miRNAs on real-time PCR instruments, ABI 7500 (Life Technologies). cDNA was synthesized from total RNA using specific stem-loop primers according to the miRNA reverse transcription protocol. The 20-µl PCR reaction mixture included 2 µl of RT product, 10 µl of SYBR® Premix Ex Taq™ PCR master mix (2X concentration), 1 µl of the forward and reverse primers each and 6 µl of nuclease-free water. The primer sequences are presented in Table I. The reactions were carried out with a 10-min incubation at 95°C followed by 40 cycles of 95°C for 15 sec and 60°C for 1 min. All reactions were run in triplicate, and the average threshold cycle and SD values were calculated. The CT value is defined as the fractional cycle number at which the fluorescence exceeds the defined threshold. The data were analyzed with automatic settings for assigning the baseline. U6 snRNA levels were used as an internal normalization control and the expression level of the miRNAs was calculated using the ΔΔCT method.

Statistical analysis. For RT-qPCR data, the relative expression levels of each target miRNA (Log2 relative level) were calculated according to the difference in CT values between the target miRNAs and U6 snRNA (ΔCT). CT values <35 were indicative of expression. Statistical analysis was performed using SPSS software version 16.0 (SPSS, Inc., Chicago, IL, USA) and GraphPad Prism 5 (GraphPad Software Inc., La Jolla, CA, USA). A P-value <0.05 was considered to indicate...
Table I. DNA sequences of the primers used for RT-qPCR.

| Name                  | DNA sequence (5'→3')                                                   |
|-----------------------|-----------------------------------------------------------------------|
| miR-451a-RT primer    | GTCGTATCCAGTGCAAGGGTCCCGAGGTATTCGACACTGGATACGACAACTCA                 |
| miR-451a-Forward primer | GAAACCGTTACCATATTACTGAG                                                |
| miR-16-5p-RT primer   | GTCGTATCCAGTGCAAGGGTCCCGAGGTATTCGACACTGGATACGACCCGCA                 |
| miR-16-5p-Forward primer | GTAGCACGCACTGAAATATTGGC                                               |
| miR-181a-5p-RT primer | GTCGTATCCAGTGCAAGGGTCCCGAGGTATTCGACACTGGATACGACACCTCAC               |
| miR-181a-5p-Forward primer | GAAATTCAACGCTGTCGGTGA                                                  |
| miR-661-RT primer     | GTCGTATCCAGTGCAAGGGTCCCGAGGTATTCGACACTGGATACGACACGCGC                |
| miR-661-Forward primer | GTGCCCTGGGTCTCGGCTGCG                                                  |
| miR-200c-3p-RT primer | GTCGTATCCAGTGCAAGGGTCCCGAGGTATTCGACACTGGATACGACACTCAC               |
| miR-200c-3p-Forward primer | GTAATACTGCGAGGATATGATG                                                 |
| miR-221-3p-RT primer  | GTCGTATCCAGTGCAAGGGTCCCGAGGTATTCGACACTGGATACGACACCCATCT              |
| miR-221-3p-Forward primer | GACCTACATTGTCTCGGTGG                                                  |
| miR-143-3p-RT primer  | GTCGTATCCAGTGCAAGGGTCCCGAGGTATTCGACACTGGATACGACAGGCTA                |
| miR-143-3p-Forward primer | GTAAACTGCGGGATTATGATG                                                  |
| miR-141-3p-RT primer  | GTCGTATCCAGTGCAAGGGTCCCGAGGTATTCGACACTGGATACGACACCCCATCT             |
| miR-141-3p-Forward primer | GTAACACTGTCGGTAAAGATG                                                    |
| miR-18a-5p-RT primer  | GTCGTATCCAGTGCAAGGGTCCCGAGGTATTCGACACTGGATACGACCTATCT                |
| miR-18a-5p-Forward primer | GTAAGGTGCACTCTGTCGCG                                                  |
| miR-523-3p-RT primer  | GTCGTATCCAGTGCAAGGGTCCCGAGGTATTCGACACTGGATACGACACCCCTC               |
| miR-523-3p-Forward primer | GGAAGCGCGCTTCCCTATAGGG                                                 |
| miR-125a-3p-RT primer | GTCGTATCCAGTGCAAGGGTCCCGAGGTATTCGACACTGGATACGACGCGCTCC               |
| miR-125a-3p-Forward primer | GACAGGTGAGGTTCGAGGAG                                                  |
| miR-30a-3p-RT primer  | GTCGTATCCAGTGCAAGGGTCCCGAGGTATTCGACACTGGATACGACGCGCTGCA              |
| miR-30a-3p-Forward primer | GCTTTGATCGGAGATGTGGTCCA                                               |
| Universal Reverse primer | GTGCAGGGGTCCCGAGGT                                                  |
| U6-RT primer          | AACGGTTCAGGAAATTGCGT                                                   |
| U6-Forward primer     | CTCGCTTCCGACGACA                                                      |
| U6-Reverse primer     | AACCGTTCACGAATTGCGT                                                   |

a statistically significant difference (Student’s t-test). For individual differentially expressed miRNAs, a receiver operating characteristic (ROC) curve was generated. The area under the curve (AUC) and 95% confidence intervals (CI) were calculated to determine the specificity and sensitivity of the miRNAs to predict fetal macrosomia.

Results

Demographics. The maternal characteristics are shown in Table II. The maternal age and pre-gestational body mass index (BMI) of the macrosomia group were higher than of those of the control group, and some women had a family history of hypertension and/or previous abortion; these data were consistent with those previously reported (27). No significant differences in gestational weight gain (GWG) were found between the pregnant women with fetal macrosomia and the women with normal pregnancies (controls) in this study. The maternal characteristics were consistent between the samples used for TLDAs and RT-qPCR.

miRNA expression profiling of plasma in pregnancies with fetal macrosomia by TRLDA. TaqMan Human miRNA Low-Density Array analysis was performed to identify circulating miRNAs exhibiting altered levels in pregnant women with fetal macrosomia, and plasma miRNAs were compared with the normal pregnancy controls. A total of 274 miRNAs incorporated in the array were detected; among these, 196 miRNAs were co-expressed; 223 and 248 miRNAs were detected in the plasma in pregnancies with fetal macrosomia and the healthy controls, respectively. To identify macrosomia-specific candidate miRNAs, the differential expression of miRNAs between the 2 groups was required to meet 2 criteria: i) CT values <35 to enable reliable detection; and ii) miRNA levels exhibiting ≥4-fold difference (ΔΔCT ≥2 or ΔΔCT ≤-2) between the macrosomia and control groups. A total of 143 miRNAs met these criteria, 43 of which were upregulated and 100 were downregulated in the pregnant women with fetal macrosomia compared with the normal pregnancy controls (Fig. 1). The top 20 differentially expressed miRNAs are listed in Table III.
Figure 1. Heatmap of differential microRNA (miRNA) expression in plasma from pregnant women with fetal macrosomia and normal controls. The expression profiles of all the miRNAs that were assayed by TaqMan Low-Density Array (TLDA) are shown. The column shows fetal macrosomia and control groups normalized to endogenous controls, and the line shows the fold change in expression of each miRNA in each group. The color of each pattern indicates the fold change as Log2 (2-ΔCt) from green to red as from −8 to 8.
Among these differentially expressed miRNAs between the pregnant women with fetal macrosomia and the normal pregnancy controls, 12 miRNAs were selected for further analysis according to TLDA results and the results of previous reports (28-30). Four selected miRNAs (miR-661, miR-523-3p, miR-125a-5p and miR-30a-3p) were upregulated and 8 miRNAs were downregulated (miR-181a-5p, miR-200c-3p, miR-143-3p, miR-221-3p, miR-16-5p, miR-141-3p, miR-18a-5p and miR-451a), which contained not only significantly differentially expressed miRNAs, but also moderately differentially expressed miRNAs. Among these, miR-661, miR-523-3p, miR-200c-3p and miR-141-3p were significantly differentially expressed, while the other miRNAs were moderately differentially expressed; the majority of these miRNAs are related to obesity (miR-143-3p, miR-221-3p, miR-125a-5p, miR-16-5p (28-30) and cancer (miR-141-3p, miR-181a-5p).

Table II. Epidemiological characteristics of pregnant women with fetal macrosomia and healthy controls.

|                        | Case          | Control       | P-value |                        | Case          | Control       | P-value |
|------------------------|---------------|---------------|---------|------------------------|---------------|---------------|---------|
| Number of samples      | 10            | 10            | -       |                        | 35            | 20            | -       |
| Maternal age (years)   | 28.34±4.67    | 25.31±3.41    | <0.001  |                        | 28.53±5.18    | 25.27±3.82    | <0.001  |
| BMI (kg/m²)            | 22.64±2.38    | 19.58±2.32    | <0.001  |                        | 22.75±2.72    | 19.41±1.74    | <0.001  |
| Previous abortion (%)  | 0             | 0             | -       |                        | 1.5%          | 0             | -       |
| Nulliparous            | 90.0%         | 100%          | -       |                        | 82.7%         | 94.0%         | -       |
| Family history of hypertension and diabetes | 19% | 0 | - | | 21% | 0 | - |
| Birth weight (kg)      | 4.87±0.43     | 3.27±0.41     | <0.001  |                        | 4.70±0.40     | 3.22±0.32     | <0.001  |
| GWG (kg)               | 15.56±4.3     | 14.18±4.26    | 0.456   |                        | 15.42±4.6     | 14.23±4.14    | 0.492   |

TLDA, TaqMan Low-Density Array; qPCR, quantitative polymerase chain reaction; BMI, body mass index; GWG, gestational weight gain.

Table III. Top 20 differentially expressed miRNAs between pregnant women with fetal macrosomia and normal controls.

| miRNA ID | ΔΔCT | miRNA ID | ΔΔCT |
|----------|------|----------|------|
| hsa-miR-661 | -15.1039 | hsa-miR-34a-5p | 17.00549 |
| hsa-miR-663b | -12.3943 | hsa-miR-208a | 16.0467 |
| hsa-miR-523-3p | -12.2455 | hsa-miR-499a-5p | 13.6248 |
| hsa-miR-198 | -9.74231 | hsa-miR-130b-3p | 13.47667 |
| hsa-miR-592 | -8.84758 | hsa-miR-7-5p | 12.7783 |
| hsa-miR-518a-3p | -8.50963 | hsa-miR-132-3p | 12.6045 |
| hsa-miR-330-3p | -7.40832 | hsa-miR-138-5p | 11.94246 |
| hsa-miR-502-5p | -7.13427 | hsa-miR-7-5p | 11.74449 |
| hsa-miR-215 | -6.94627 | hsa-miR-381 | 11.6779 |
| hsa-miR-489 | -6.88626 | hsa-miR-9-5p | 10.87772 |
| hsa-miR-485-3p | -6.44884 | hsa-miR-331-5p | 10.59712 |
| hsa-miR-525-5p | -6.27043 | hsa-miR-149-5p | 10.59156 |
| hsa-miR-26a-2-3p | -6.12089 | hsa-miR-299-3p | 10.18141 |
| hsa-miR-1254 | -5.94441 | hsa-miR-708-5p | 9.921302 |
| hsa-miR-373-3p | -5.61778 | hsa-miR-200c-3p | 9.433656 |
| hsa-miR-1255b-5p | -5.3922 | hsa-miR-29b-3p | 9.103284 |
| hsa-miR-432-5p | -5.14086 | hsa-miR-208b | 8.918743 |
| hsa-miR-31-3p | -5.04041 | hsa-miR-576-3p | 8.858621 |
| hsa-miR-589-5p | -4.83138 | hsa-miR-638 | 8.628476 |
| hsa-miR-1274a | -4.30028 | hsa-miR-545-3p | 8.504154 |

miRNAs, microRNAs.
miR-18a-5p, miR-30a-3p) (31). miR-451a was highly abundant in red blood cells. It is also the most abundant miRNA in the sequencing data of our previously published study on abormal pregnancy (32).

Fig. 2 shows the qPCR confirmation results, which indicated that the differential expression obtained in the majority of the selected miRNAs between pregnant women with fetal macrosomia and the normal controls were consistent. The results confirmed the upregulated miRNAs, miR-523-3p, miR-125a-5p, miR-661; and miR-221-3p, miR-451a, miR-143-3p, miR-18a-5p, miR-141-3p, miR-181a-5p and miR-200c-3p were confirmed as downregulated miRNAs in the plasma from pregnant women with macrosomia, while opposite results were obtained by RT-qPCR as regards miR-16-5p when compared with the TLDA results.

**RT-qPCR of miRNA expression in plasma from pregnant women with fetal macrosomia.** The majority of the miRNAs selected for verification were confirmed and quantified by RT-qPCR. Although no reliable endogenous control miRNA has been identified in studying circulating miRNAs (33,34), U6 snRNA is still the most common choice. Therefore, we used U6 snRNA as the endogenous control in this study and the expression levels of the miRNAs were normalized to U6 snRNA [Log2 (fold change)]. The expression levels of miR-221-3p, miR-143-3p, miR-18a-5p, miR-141-3p and miR-200c-3p were significantly lower in the plasma from women with fetal macrosomia compared with the normal controls (P<0.001, P<0.05, t-test). The levels of miR-523-3p, miR-30a-3p and miR-16-5p were significantly higher in the plasma from pregnant women with fetal macrosomia, while no significant differences were detected in the expression levels of miR-181a-5p, miR-661, miR125a and miR-451a. The results are shown in Fig. 3.

**Evaluation of the diagnostic potential of miRNAs for fetal macrosomia.** To investigate the characteristics of these miRNAs as potential diagnostic biomarkers of fetal macrosomia, ROC curve analysis was performed on the miRNAs exhibiting significant differences in expression. The ROC curves of miR-30a-3p, miR-143-3p and miR-18a-5p exhibited a moderate distinguishing efficiency with an AUC value of 0.807 (95% CI), 0.802 (95% CI) and 0.841 (95% CI), respectively (Fig. 4A, C and D). miR-221-5p and miR-16-5p showed a relatively lower distinguishing efficiency with an AUC value of 0.680 (95% CI) and 0.674 (95% CI) (Fig. 4G and H), while miR-523-3p, miR200c and miR141 exhibited a higher distinguishing efficiency with an AUC value of 0.909 (95% CI), 0.948 (95% CI) and 0.940 (95% CI), respectively, which reflected a marked difference between the pregnant women with fetal macrosomia and those with normal pregnancy (controls) (Fig. 4B, E and F).

To verify the specificity of the miRNAs for fetal macrosomia, the 3 miRNAs with higher distinguishing efficiency from the plasma pools of abnormal pregnancy due to preeclampsia were also detected. Fig. 5 shows the results of the comparison between pregnant women with fetal macrosomia and pregnant women with preeclampsia. More specifically, miR-141-3p and miR-200c-3p showed significant differences, whereas no significant differences were observed for miR-523-3p (P=0.076). All 3 miRNAs were found to be upregulated in the pregnant women with preeclampsia, while miR-141-3p and miR-200c-3p were downregulated in the pregnant women with fetal macrosomia.

Four miRNA clusters were found to be differentially expressed in the maternal plasma of pregnant women with fetal macrosomia. A comparison of their expression levels indicated that the expression levels of the cluster members changed with a similar trend (Fig. 6). The results of ROC curve analysis...
revealed that the combination of the miRNA cluster members showed greater sensitivity and specificity. This suggested that the combination of the miRNA cluster members showed greater distinguishing efficiency for the diagnosis of fetal macrosomia. Furthermore, ROC curve analysis showed greater distinguishing efficiency when the miRNAs were combined with BMI and GWG (data not shown).

Effect of pre-pregnancy BMI and GWG on fetal macrosomia. In this study, the effects of BMI and GWG on fetal macrosomia were also investigated. BMI is a measure of relative weight based on an individual's mass and height, and has been reported to be related to obesity, diabetes mellitus, etc. The question addressed in the present study was whether a woman's aberrant BMI level is associated with a greater risk of delivering an overweight newborn. Significant birth weight differences were found between the pregnant women with different BMIs (P<0.001), particularly those with a BMI >25 or BMI <18. GWG is another relevant factor that may be associated with fetal macrosomia. In this study, the results revealed that pregnant women with a GWG <10 or a GWG >20 were at a greater risk of carrying a macrosomic fetus (data not shown).

Discussion

In the present study, circulating miRNAs in maternal plasma in pregnancies with fetal macrosomia were detected and analyzed. Although miRNAs have been extensively investigated as novel and non-invasive diagnostic and prognostic markers in various types of cancer and abnormal pregnancies (32,35-37), to the best of our knowledge, this is the first comprehensive survey on maternal circulating miRNA expression profiles in maternal plasma from pregnant women with fetal macrosomia. We investigated circulating miRNAs in the maternal plasma from pregnant women with fetal macrosomia by TLDAs. Differentially expressed miRNAs were profiled, and some of them were validated by RT-qPCR. Although the concentration of circulating miRNAs in maternal plasma is rare, 274 types of miRNAs were detected with TLD. Among these, a total of 196 miRNAs were co-expressed; 27 and 52 miRNAs were detected only in the plasma of carriers of macrosomic fetuses and healthy controls, respectively. Forty additional individual plasma samples were detected by RT-qPCR as validation since only 2 pooled samples (each included 10 individual samples) were measured.
GE et al: CIRCULATING miRNAs IN PREGNANCIES WITH FETAL MACROSOMIA

by TLDA. Twelve miRNAs were selected for RT-qPCR based on the TLDA results; consistent results were obtained for all of the miRNAs apart from miR-16-5p (Fig. 1). This inconformity may be mainly due to the individual differences of the investigated plasma samples.

To evaluate the efficiency of these selected dysregulated miRNAs for the diagnosis of fetal macrosomia, ROC curves were constructed for each miRNA. miR-141-3p, miR-523-3p, and miR-200c-3p showed the ability to distinguish fetal macrosomia from normal control pregnancy efficiently, with an AUC
value >0.9. In addition, miR-141-3p and miR-200c-3p showed the ability to distinguish fetal macrosomia from other types of abnormal pregnancy, such as preeclampsia. These miRNAs may thus be potential biomarkers for the detection and diagnosis of fetal macrosomia and other complications associated with pregnancy. However, the biological mechanisms of the dysregulation of these miRNAs and their therapeutic potential in fetal macrosomia require further investigation.

We also analyzed the expression of miRNA clusters. Of note, the results revealed that cluster members showed similar changes in expression in pregnancy (Fig. 6). miRNA clusters are largely present in metazoan genomes with the diversity of their distribution (38). A number of miRNAs are linked as clusters on chromosomes and are often transcribed from genomic DNAs as a single polycistronic transcript to provide the opportunity for different miRNAs to target several categories of genes simultaneously (39,40). Accumulating evidence suggests that clustered miRNAs are always transcribed as polycistrons and have similar expression patterns (41). In this study, we observed the characteristics of miRNA cluster expression patterns. Four miRNA clusters, the miR-451, miR-17-92, miR-27 and miR-141 clusters were found to be significantly differentially expressed in the plasma from pregnant women with fetal macrosomia. Although their expression levels differed, the results revealed that the changes in the expression of the cluster members showed a similar trend when compared to the expression patterns.

Maternal obesity, impaired glucose tolerance, gestational diabetes and high BMI may all contribute to infant macrosomia (6,9). In this study, we detected the miRNA expression and analyzed the correlation between BMI and miRNA expression levels. miRNAs, such as miR-143-3p and miR-221-3p have been reported to be related to obesity and diabetes (28-31), as
miRNA-143 inhibits insulin-stimulated AKT activation and impairs glucose metabolism. These miRNAs were also found to be significantly differentially expressed in the plasma of pregnant women with fetal macrosomia in this study, while opposite trends in expression were observed in our study. For instance, mir-143-3p has shown an upregulated expression in obesity (30), while its expression was downregulated in the pregnant women with fetal macrosomia in our study. We hypothesized that miRNAs may show a compensatory reverse expression in childhood and in adulthood compared with the embryonic phase.

GWG is also greatly considered a factor that may be related to abnormal pregnancy. Although no significant differences in GWG were observed between the macrosomia and the control groups in this study, surprisingly, it was found that infants with the highest birth weight were delivered by women with the lowest GWG. Therefore, the association between GWG, miRNAs and macrosomia requires further investigation.

The differentially expressed miRNAs which were detected by TLDAs with a ΔΔCT value >2.0 or < -2.0 in pregnant women with fetal macrosomia compared with the normal pregnancy controls, were regarded as macrosomia-specific plasma miRNAs. We collected their experimentally validated target sites from the miRTarBase database (42). Those genes targeted by >2 miRNAs were regarded as target genes of maternal plasma miRNAs. We analyzed functions and functional relationships of these target genes using Gene Ontology Analysis and Kyoto Encyclopedia of Genes and Genomes (KEGG). The results revealed that genetic disorders, immunological disease, cell signaling, cancer and cell cycle were the enriched pathways of maternal plasma miRNA target genes (data not shown). These pathways are closely related to pregnancy progression. Therefore, maternal plasma miRNAs may participate in the regulation of pregnancy through these pathways.

This study had several limitations which should be noted. Firstly, only partially dysregulated miRNAs were selected and evaluated, while other differentially expressed miRNAs were not detected in this study. More efficient biomarkers and significant miRNAs may still be detected for research on fetal macrosomia. Secondly, our study is a preliminary investigation of miRNA expression levels associated with abnormal pregnancy, fetal macrosomia in particular, and provides a platform for related research. More information is required on biomarkers, including exact differences in individual pregnancies, as well as in situations of other types of abnormal pregnancy. More importantly, the functions and miRNA regulatory pathways should be thoroughly investigated. Furthermore, additional research conducted on larger numbers of pregnant women (abnormal pregnancies and normal controls) and non-pregnant healthy controls is required to validate our findings.

In conclusion, TLDAs revealed the dysregulation of 143 miRNAs in the maternal plasma from pregnant women with fetal macrosomia. mir-141-3p and mir-200c-3p were shown to be able to distinguish pregnancies with fetal macrosomia from healthy pregnancies and other types of abnormal pregnancy with high sensitivity and specificity. Strong correlations were observed between miRNA expression levels and BMI. It was also revealed that the expression of miRNA clusters showed the same changing trend in fetal macrosomia. This suggests that altered levels of miRNAs in maternal plasma have great potential to serve as non-invasive and mechanistically relevant biomarkers for the detection and diagnosis of abnormal pregnancies.

Acknowledgements

This study was supported by projects 61271055, 61271054 and 61372164 of the National Natural Science Foundation of China.

References

1. Boulet SL, Alexander GR, Salihu HM and Pass M: Macrosomic births in the united states: determinants, outcomes, and proposed grades of risk. Am J Obstet Gynecol 188: 1372-1378, 2003.
2. Henriksen T: The macrosomic fetus: a challenge in current obstetrics. Acta Obstet Gynecol Scand 87: 134-145, 2008.
3. Schwartz R and Teramo KA: What is the significance of macrosomia? Diabetes Care 22: 1201-1205, 1999.
4. Haram K, Pirhonen J and Bergsjo P: Suspected big baby: a difficult clinical problem in obstetrics. Acta Obstet Gynecol Scand 81: 185-194, 2002.
5. Ehrenberg HM, Mercer BM and Catalano PM: The influence of obesity and diabetes on the prevalence of macrosomia. Am J Obstet Gynecol 191: 964-968, 2004.
6. Jang HC, Cho NH, Min YK, Han JK, Jung KB and Metzger BE: Increased macrosomia and perinatal morbidity independent of maternal obesity and advanced age in Korean women with GDM. Diabetes Care 20: 1582-1588, 1997.
7. Yu Z, Sun JQ, Haas JD, Gu Y, Li Z and Lin X: Macrosomia is associated with high weight-for-height in children aged 1-3 years in Shanghai, China. Int J Obes (Lond) 32: 55-60, 2008.
8. Segregur J, Bukovic D, Milinovic D, et al: Fetal macrosomia in pregnant women with gestational diabetes. Coll Antropol 33: 1121-1127, 2009.
9. Suhonen L, Hiilesmaa V, Kaaja R and Teramo K: Detection of pregnancies with high risk of fetal macrosomia among women with gestational diabetes mellitus. Acta Obstet Gynecol Scand 87: 940-945, 2008.
10. Vohe BR and Boney CM: Gestational diabetes: the forerunner for the development of maternal and childhood obesity and metabolic syndrome? J Matern Fetal Neonatal Med 21: 149-157, 2008.
11. Örnoy A: Prenatal origin of obesity and their complications: Gestational diabetes, maternal overweight and the paradoxical effects of fetal growth restriction and macrosomia. Reprod Toxicol 32: 205-212, 2011.
12. Van Assche FA, Holemans K and Aerts L: Long-term consequences of offspring of diabetes during pregnancy. Br Med Bull 60: 173-182, 2001.
13. Kim YS, Yoon YJ, Jatoi I and Kim Y: Fetal macrosomia in experimental maternal diabetes. Am J Obstet Gynecol 139: 27-32, 1981.
14. Bartel DP: MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116: 281-297, 2004.
15. Mattick JS and Makunin IV: Non-coding RNA. Hum Mol Genet 15 Spec No 1: R17-R29, 2006.
16. Mitchell PS, Parkin RK, Kroh EM, et al: Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci USA 105: 10513-10518, 2008.
17. Reid G, Kirschner MB and van Zandwijk N: Circulating microRNAs: Association with disease and potential use as biomarkers. Crit Rev Oncol Hematol 80: 193-208, 2011.
18. Tan KS, Armugam A, Sepramaniam S, et al: Expression profile of microRNAs in young stroke patients. PLoS One 4: e7689, 2009.
19. Zampetaki A, Willeit P, Drozdov I, Kiechl S and Mayr M: Profiling of circulating microRNAs: from single biomarkers to re-wired networks. Cardiovasc Res 93: 555-562, 2012.
20. Wang G, Tam LS, Li EK, et al: Serum and urinary free microRNA level in patients with systemic lupus erythematosus. Lupus 20: 493-500, 2011.
21. Corsten MF, Dennert R, Jochems S, et al: Circulating microRNA-208b and microRNA-499 reflect myocardial damage in cardiovascular disease. Circ Cardiovasc Genet 3: 499-506, 2010.
22. Ng EK, Tsang WP, Ng SS, et al: MicroRNA-143 targets DNA methyltransferases 3A in colorectal cancer. Br J Cancer 101: 699-706, 2009.

23. Huang Z, Huang D, Ni S, Peng Z, Sheng W and Du X: Plasma microRNAs are promising novel biomarkers for early detection of colorectal cancer. Int J Cancer 127: 118-126, 2010.

24. Chen X, Ba Y, Ma L, et al: Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res 18: 997-1006, 2008.

25. Ng EK, Tsui NB, Lau TK, Leung TN, Chiu RW, Panesar NS, Lit LC, Chan KW and Lo YM: mRNA of placental origin is readily detectable in maternal plasma. Proc Natl Acad Sci USA 100: 4748-4753, 2003.

26. Fanson BG, Osmack P and Di Bisceglie AM: A comparison between the phenol-chloroform method of RNA extraction and the QIAamp viral RNA kit in the extraction of hepatitis C and GB virus-C/hepatitis G viral RNA from serum. J Virol Methods 89: 23-27, 2000.

27. Liu J, Leng J, Tang C, Liu G, Hay J, Wang J, Wen S, Li Z and She Y: Maternal glucose level and body mass index measured at gestational diabetes mellitus screening and the risk of macrosomia: results from a perinatal cohort study. BMJ Open 4: e004538, 2014.

28. Prats-Puig A, Ortega FJ, Mercader JM, et al: Changes in circulating microRNAs are associated with childhood obesity. J Clin Endocrinol Metab 98: E1655-E1660, 2013.

29. Ortega FJ, Mercader JM, Catalán V, et al: Targeting the circulating microRNA signature of obesity. Clin Chem 59: 781-792, 2013.

30. Jordan SD, Krüger M, Willmes DM, et al: Obesity-induced overexpression of miRNA-143 inhibits insulin-stimulated AKT activation and impairs glucose metabolism. Nat Cell Biol 13: 434-446, 2011.

31. Fu T, Choi SE, Kim DH, et al: aberrantly elevated miRNA-34a in obesity attenuates hepatic responses to FGF19 by targeting a membrane coreceptor β-Klotho. Proc Natl Acad Sci USA 109: 16137-16142, 2012.

32. Yang Q, Lu J, Wang S, Li H, Ge Q and Lu Z: Application of next-generation sequencing technology to profile the circulating microRNAs in the serum of preeclampsia versus normal pregnant women. Clin Chim Acta 412: 2167-2173, 2011.

33. Davoren PA, McNeill RE, Lowery AJ, Kerin MJ and Miller N: Identification of suitable endogenous control genes for microRNA gene expression analysis in human breast cancer. BMC Mol Biol 9: 76, 2008.

34. Xie T, Liang J, Guo R, Liu N, Noble PW and Jiang D: Comprehensive microRNA analysis in bleomycin-induced pulmonary fibrosis identifies multiple sites of molecular regulation. Physiol Genomics 43: 479-487, 2011.

35. Cortez MA, Welsh JW and Calin GA: Circulating microRNAs as noninvasive biomarkers in breast cancer. Recent Results Cancer Res 195: 151-161, 2012.

36. Bianchi F, Nicassio F, Marzi M, et al: A serum circulating miRNA diagnostic test to identify asymptomatic high-risk individuals with early stage lung cancer. EMBO Mol Med 3: 495-503, 2011.

37. Chen X, Hu Z, Wang W, et al: Identification of ten serum microRNAs from a genome-wide serum microRNA expression profile as novel noninvasive biomarkers for nonsmall cell lung cancer diagnosis. Int J Cancer 130: 1620-1628, 2012.

38. Zhang Y, Zhang R and Su B: Diversity and evolution of microRNA gene clusters. Sci China C Life Sci 52: 261-266, 2009.

39. Kim VN and Nam JW: Genomics of microRNA. Trends Genet 22: 165-173, 2006.

40. Xu J and Wong C: A computational screen for mouse signaling pathways targeted by microRNA clusters. RNA 14: 1276-1283, 2008.

41. Baskerville S and Bartel DP: Microarray profiling of microRNAs reveals frequent coexpression with neighboring miRNAs and host genes. RNA 11: 241-247, 2005.

42. Hsu SD, Lin FM, Wu WY, et al: miRTarBase: a database curates experimentally validated microRNA-target interactions. Nucleic Acids Res 39: D163-D169, 2011.